



SYMPOSIUM

National Lung Cancer Partnership Annual Meeting Friday, June 1, 2007

8:00 AM–12:00 PM
Chicago Marriott Downtown

For registration details:
www.nationallungcancerpartnership.org

Agenda

7:00–8:00am *Registration & Breakfast*

8:00–8:15am *Welcome & Introductions*
Joan H. Schiller, MD

8:15–8:55am *How Public Policy Impacts Lung Cancer Rates*
Carolyn Dresler, MD, MPA

8:55–9:50am *Panel Discussion: CT Screening for Lung Cancer: What More Do We Need to Know?*
Moderator: Kathy Albain, MD
Panelists: Claudia Henschke, MD & Denise Aberle, MD

9:50–10:05am *Break*

Advocacy Session

10:05–11:50am *How They Got Started and Made Their Voice Heard*
Panelists: B.J. Stiles, Founder, National Leadership Coalition on AIDS; Carolina Hinestrosa, National Breast Cancer Coalition

Scientific Sessions

10:10–10:25am *Epigenetics and Sex Differences in Lung Cancer*
Christoph Plass, PhD

10:25–10:45am *Understanding Drug Resistance and How to Overcome It*
Hayley McDaid, PhD

10:45–11:50am *Bronchoalveolar Carcinoma (BAC): Clinical, Scientific, and Pathologist Perspectives*
Moderator: Antoinette Wozniak, MD
Panelists: Elizabeth Brambilla, MD, Vincent Miller, MD, & Pasi Janne, MD, PhD

11:50am–Noon *Concluding Remarks*
Joan H. Schiller, MD

POSTER PRESENTATIONS

General Lung Cancer Session Saturday, June 2, 2007

Poster Display 8:00am – 1:00pm E451a
Poster Presentation 12:00–1:00pm E354a

[Poster 23, Abstract 7549] Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials.

Presenter: Kathy Albain, MD

General Lung Cancer Session Sunday, June 3, 2007

Poster Display 8:00am–12:00pm
S Hall A2

[Poster T7, Abstract 7637] Single-agent compared to combination first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2.

Presenter: Philip Bonomi, MD

[Poster Z4, Abstract 7683] Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2.

Presenter: Helen J. Ross, MD

PUBLICATION ONLY

[15130] Paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for esophageal and gastric cancer: a phase I study.

Authors: *Dipetrillo, Evans, Akerman, Miner, Millis, Jean, Henderson, Oldham, Eisenfeld, Safran*

[18036] Serum cathepsin B levels are prognostic in chemotherapy-naïve advanced NSCLC PS2 patients; analysis of results from STELLAR 3 and 4.

Authors: *Singer, Oldham, Bandstra, Sandalic, Bianco, Bonomi, Ross*

[18172] Medical resource utilization and costs associated with XYOTAX™ (CT-2103, paclitaxel poliglumex, PPX) compared to gemcitabine or vinorelbine in the treatment of non-small cell lung cancer patients.

Authors: *Oldham, Anastassopoulos, O'Bryne, Maxon, Schaefer*